Confluence Investment Management LLC Buys 459 Shares of Roche Holding AG (OTCMKTS:RHHBY)

Confluence Investment Management LLC raised its holdings in shares of Roche Holding AG (OTCMKTS:RHHBY) by 3.7% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 12,922 shares of the company’s stock after acquiring an additional 459 shares during the period. Confluence Investment Management LLC’s holdings in Roche were worth $448,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. AlphaMark Advisors LLC acquired a new position in Roche in the 1st quarter worth $34,000. Wetzel Investment Advisors Inc. acquired a new position in Roche in the 4th quarter worth $53,000. First Horizon Advisors Inc. boosted its stake in Roche by 19.8% in the 4th quarter. First Horizon Advisors Inc. now owns 2,066 shares of the company’s stock worth $75,000 after purchasing an additional 342 shares during the period. GAMMA Investing LLC acquired a new position in shares of Roche during the 4th quarter worth about $146,000. Finally, Waldron Private Wealth LLC acquired a new position in shares of Roche during the 4th quarter worth about $294,000.

Roche Stock Performance

Shares of OTCMKTS RHHBY traded down $0.01 during trading on Monday, hitting $40.71. 1,483,500 shares of the company traded hands, compared to its average volume of 2,465,619. The business’s fifty day moving average is $35.56 and its 200 day moving average is $33.38. Roche Holding AG has a fifty-two week low of $29.20 and a fifty-two week high of $41.15. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.35 and a quick ratio of 1.04.

Wall Street Analyst Weigh In

Several research analysts have weighed in on RHHBY shares. Deutsche Bank Aktiengesellschaft raised shares of Roche from a “sell” rating to a “hold” rating in a report on Friday, May 17th. The Goldman Sachs Group assumed coverage on shares of Roche in a research report on Thursday, May 30th. They set a “sell” rating on the stock. Two investment analysts have rated the stock with a sell rating and five have given a hold rating to the company. According to data from MarketBeat, Roche presently has a consensus rating of “Hold” and a consensus target price of $40.00.

About Roche

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.